Aspire Biopharma Holdings, Inc. (ASBP)

Aspire Biopharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	0.61	0.29	0.42
Research & Development	0.04	0.07	0.18
Operating Expenses	0.65	0.36	0.6
Operating Income	-0.65	-0.36	-0.6
Pretax Income	-0.65	-0.36	-0.6
Income Tax Expense	0	0	0
Net Income	-0.65	-0.36	-0.6
Net Income to Common	-0.65	-0.36	-0.6
Shares Outstanding (Basic)	443	443	-
Shares Outstanding (Diluted)	443	443	-
EPS (Basic)	-0.00	-0.00	-
EPS (Diluted)	-0.00	-0.00	-
EBIT	-0.65	-0.36	-0.6

Updated Jan 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.